Stockwinners Market Radar for October 21, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:05 EDT Vonage accelerates expansion into Asia Pacific - Vonage is continuing its expansion throughout the Asia-Pacific region with a second Australia office. Located in Melbourne, the office will provide a facility for the company's sales and customer support teams.

19:48 EDT Twitter plans to update rules to address manipulated media on its platform - The official Twitter Safety (@TwitterSafety) account tweeted: "We're always updating our rules based on how online behaviors change. We're working on a new policy to address synthetic and manipulated media on Twitter - but first we want to hear from you. What's synthetic and manipulated media? It's media that's been significantly altered or created in a way that changes the original meaning/purpose, or makes it seem like certain events took place that didn't actually happen. The new policy will address this type of content, specifically when it could threaten someone's physical safety or lead to offline harm. In the coming weeks, we'll announce a feedback period so that you can help us refine this policy before it goes live. Stay tuned for more!"

19:29 EDT Nvidia, Ericsson collaborate on virtualized 5G radio access technology - NVIDIA (NVDA) and Ericsson (ERIC) announced they are collaborating on technologies that can allow telco operators to build completely virtualized 5G radio access networks. These virtualized networks can enable "faster and more flexible" introduction of new AI and IoT services. The collaboration, announced by NVIDIA founder and CEO Jensen Huang at a keynote ahead of the start of MWC Los Angeles, brings together "Ericsson's expertise in RAN technology with NVIDIA's leadership in GPU-powered accelerated computing platforms".

18:43 EDT Nvidia, Red Hat to deliver 5G wireless infrastructure to telecom industry - Nvidia (NVDA) and Red Hat (IBM) announced they are expanding their alliance to deliver high-performance, software-defined 5G wireless infrastructure, running on Red Hat OpenShift, to the telecom industry. The collaboration, unveiled by NVIDIA founder and CEO Jensen Huang during his keynote at MWC Los Angeles, can help telcos transition to 5G networks capable of running a range of software-defined edge workloads, the companies said. Work will initially focus on 5G radio access networks, aimed at making AI-enabled applications more accessible at the telco edge.

17:45 EDT Four Corners Property Trust acquires Maryland property for $2M - Four Corners Property Trust announced the acquisition of a Longhorn restaurant property for $2.0M from Brookfield Properties. The property is an outparcel to a Brookfield owned mall located in Maryland and is occupied under a triple-net lease with approximately three years of term remaining. The transaction is a continuation of the six-property acquisition closed in November 2018 and was priced at a similar going-in cash capitalization rate as previously announced transactions.

17:32 EDT Centene announces $500M share repurchase plan - In a regulatory filing, Centene (CNC) disclosed that on October 18 its Board of Directors authorized the repurchase of up to $500M of shares of the company's common stock. Under the Increased repurchase amount, the company may use some or all of the proceeds from divestitures related to the WellCare (WCG) acquisition to repurchase shares. The authorization to repurchase $500M of common stock is in addition to the previously approved stock repurchase program which authorized the repurchase of up to 16M shares of common stock, of which 6.7M shares remain as of October 21.

17:23 EDT Renasant board approves new $50M share repurchase program - "We closed the quarter with solid results and maintained strong performance ratios despite feeling the impact from Durbin for the first time," said Renasant Chairman, E. Robinson McGraw. "We completed our previously announced $50 million share repurchase program in early October and our Board approved another $50 million share repurchase program. Additionally during the third quarter, we redeemed the subordinated notes we assumed as part of the Brand acquisition. The repurchase programs support our strategy of returning capital to our shareholders while also maintaining a strong capital position."

17:20 EDT TD Ameritrade up 5% to $39.55 after Q4 results beat estimates

17:10 EDT 2K and Nike announce NBA 2K20 x Nike Gamer Exclusive Program - 2K (TTWO) and Nike (NKE) announced the NBA 2K20 x Nike Gamer Exclusive Program, "a first-of-its-kind gaming and sneaker partnership, which launches alongside the new MyPLAYER Nation mode and NBA season tip-off, on October 22. The Program will allow NBA 2K20 players the opportunity to earn up to 10 pairs of soon-to-be-released virtual Nike Basketball signature shoes for their MyPLAYER by completing in-game challenges and the chance to purchase the real-life version of the limited-edition shoes from Nike. MyPLAYER is NBA 2K's player creation feature that allows gamers the opportunity to build their own basketball player, get drafted, rise through the ranks of the NBA elite, and help take their team to glory. "We're excited to be the first sports game to offer our players the chance to buy exclusive shoes from their favorite Nike athletes," said Alfie Brody, VP of Global Marketing at 2K. "We always strive to push the boundaries of in-game partnerships and offer our players unique experiences alongside traditional basketball gameplay. We can't wait to see our fans progress through the challenges to unlock and purchase each pair," said the companies.

16:54 EDT Stamps.com up 20% at $91.50/shr after entering logistics services deal with UPS

16:41 EDT Carlisle to acquire Providien, terms not stated - Carlisle announced the signing of a definitive agreement to acquire Providien LLC, a provider of manufacturing solutions for global medical device OEMs, including: thermoforming, medical device contract manufacturing, precision machining & metals, and medical injection molding. Providien will become part of the Carlisle Interconnect Technologies operating segment. The transaction is expected to close in Q4 of 2019. Based in San Diego, California, and with over 1,000 employees, Providien has additional facilities in California and Tijuana, Mexico.

16:38 EDT Cadence Design up 4.5% at $69.72 after Q3 earnings beat, FY19 guidance raise

16:36 EDT HomeStreet board approves additional share buyback of up to $25M - HomeStreet said its board has approved an additional share repurchase program for up to $25M in aggregate amount of shares of the company's common stock, no par value, from shareholders, which represents approximately 3.8% of the company's currently outstanding common stock based on the closing price of the stock as of September 30, 2019. This repurchase is in addition to the 2.7M shares of common stock that the company repurchased earlier this year through open market repurchases made during the second quarter and a negotiated repurchase from a group of investors that was completed during the third quarter.

16:33 EDT Norbord to indefinitely curtail production on Line 1 at Cordele OSB mill - Nobord announced that effective mid-November, it will indefinitely curtail production on Line 1 of its two-line oriented strand board mill in Cordele, Georgia until further notice. Cordele Line 1 has been operating on a reduced 10/4 operating schedule since early September. Cordele Line 2 will continue to operate on a full production schedule. The Cordele Line 1 indefinite curtailment is due to continued poor market conditions and lower-than-anticipated OSB demand to-date, particularly in the South East region. These conditions no longer support the economic operation of Line 1 at this time. The indefinite curtailment will ensure Norbord continues to only produce what the company can sell, in the most efficient and cost-effective manner. Norbord will continue to serve its customers without disruption from Cordele Line 2 and from its other operating OSB mills in North America. The Cordele, Georgia mill has two production lines and a total stated annual production capacity of 1,040 million square feet. The indefinite curtailment of Line 1 will affect 440 MMsf or 42% of the mill's available capacity. Approximately 45 employees will be impacted by this curtailment. As a result of this curtailment, the Company will record a non-cash pre-tax impairment charge of $10M against the carrying value of the Cordele mill's fixed assets as part of its third quarter 2019 earnings results.

16:30 EDT Obsidian Energy CFO David Hendry resigns - Obsidian Energy said that CFO David Hendry has submitted his resignation, effective November 15, 2019 to pursue another opportunity. Obsidian Energy is currently in discussions to secure a successor and expects to announce a replacement in the near future. Michael Faust, interim President and Chief Executive Officer, stated, "We thank David for his years of dedication and leadership to the Company, particularly in the role of CFO, and wish him every success in his future endeavors."

16:24 EDT Hexcel reports Q3 gross margin 27.6% vs. $26.5% last year - Reports Q3 operating margin 19.2% vs. 17.9% last year.

16:22 EDT Braemar Hotels & Resorts declares distribution of shares of Ashford - Braemar Hotels & Resorts (BHR) announced that its Board of Directors has formally declared the distribution of its remaining 174,983 shares of common stock of Ashford (AINC). Both common stockholders and unitholders of Braemar will receive their pro-rata share of Ashford common stock. The distribution to Braemar common stockholders will be completed through a pro-rata, taxable dividend of Ashford common stock on November 5 to stockholders of record as of the close of business of the NYSE on October 29.

16:20 EDT Kadmon announces FDA approval for Clovique - Kadmon announced that the FDA has approved Clovique, a room-temperature stable, branded generic product. Trientine hydrochloride is used for the treatment of Wilson's disease in patients who are intolerant of penicillamine. Clovique is the first FDA-approved trientine product in a portable blister pack that offers room temperature stability for up to 30 days. Kadmon has immediately commenced commercialization activities for Clovique hrough Kadmon Pharmaceuticals, its wholly-owned commercial operation.

16:19 EDT First BanCorp to acquire FirstBank Puerto Rico for $425M - First BanCorp announced the signing of a stock purchase agreement for FirstBank to acquire Banco Santander Puerto Rico for a $63M premium to BSPR's core tangible common equity in an all cash transaction. As of June 30, 2019, BSPR had $6.2B of assets, $3.1B of loans and $5.0B of deposits. On a pro forma basis based on June 30, 2019 data, including purchase accounting adjustments, after the transaction FirstBank will have approximately $17.6B in assets, a $12.0B loan portfolio, and $14.2B of deposits. Transaction Highlights: 100% cash transaction, $425M base purchase price, or 117.5% of BSPR's core tangible common equity, comprised of a $63M premium on $362M of core tangible common equity as of June 30, 2019; plus $638M of BSPR's excess capital as of June 30, 2019 paid at par; purchase price is subject to adjustment based on BSPR's balance sheet as of the closing date. The transaction is expected to be 35% accretive to 2020 consensus EPS of 81c.

16:17 EDT LegacyTexas Financial notifies NASDAQ of date of merger with Prosperity - LegacyTexas Financial Group announced that it has notified NASDAQ of the anticipated effective date of the previously-announced proposed merger with Prosperity Bancshares contemplated by that certain Agreement and Plan of Reorganization, dated as of June 16. LegacyTexas anticipates that the merger will be effective as of November 1 subject to the approval of the shareholders of Prosperity and the stockholders of LegacyTexas and the satisfaction or waiver of the other closing conditions described in the definitive merger agreement.

16:15 EDT UPS in pact with Stamps.com as part of Digital Access Program - UPS (UPS) unveiled its strategy to make industry-leading logistics services more broadly available through a series of strategic alliances and agreements called the UPS Digital Access Program. As the retail industry continues to transform, UPS has prioritized e-commerce growth by enhancing its network and services to enable faster deliveries, enhanced visibility and a broader range of delivery options. With the UPS Digital Access Program, UPS is establishing preferred relationships with leading digital platforms to enhance various aspects of the e-commerce value stream. These platforms seamlessly provide discounted UPS shipping rates and other shipping and logistics solutions to their merchant customers. "By embedding UPS natively into popular e-commerce platforms, merchants will get the breadth and reliability of UPS's services to more than 220 countries and territories," said Kevin Warren, Chief Marketing Officer at UPS. "More small and medium-sized businesses will now have access to UPS, helping them offer industry-leading delivery commitments and leveling the highly competitive e-commerce playing field Online business-to-business and business-to-consumer transaction growth shows no signs of abating. eMarketer estimates global e-commerce gross merchandise value will grow from $3.5 trillion today to $6.5 trillion by 2023. This has a tremendous impact on the shipping industry due to package volume growth while driving the digitization of the entire e-commerce value stream, from inventory procurement to order management, delivery and returnsThe UPS Digital Access Program helps e-commerce platforms provide a comprehensive suite of order management, fulfilment and delivery services to simplify logistics complexity. This gives SMBs the opportunity to provide the same high-quality customer experience as large e-commerce companies. As part of the Digital Access Program, UPS has signed an agreement with Stamps.com (STMP), the leading provider of e-commerce shipping software, to offer discounted shipping rates to Stamps.com's customer base of more than 740,000. Stamps.com offers a portfolio of Internet shipping software solutions under the brand names ShipStation, ShippingEasy, ShipWorks, Stamps.com and Endicia. These solutions help small and medium-sized e-commerce businesses run their shipping operations more smoothly and successfully. With the Digital Access Program, Stamps.com customers now have the option to easily access UPS's shipping services at discounted rates.

16:13 EDT Agree Realty raises FY19 acquisition guidance to $650M-$700M - The company said, "We are very pleased with another extremely strong quarter of execution. While achieving near record quarterly acquisition volume, we continued our mission to create the country's highest quality retail portfolio, with more than 85% of rent acquired during the quarter derived from leading investment grade retailers. Given our strong year-to-date acquisition activity and improved visibility into the pipeline for the remainder of 2019, we are increasing our full-year acquisition guidance to a range of $650M to $700M."

16:11 EDT Vertex raises 2019 cystic cystic fibrosis sales outlook to $3.7B-$3.75B - Vertex said in a regulatory filing, "With the early approval of TRIKAFTA, we are increasing our guidance for full-year 2019 CF net product revenues to $3.70 billion - $3.75 billion. Our previous guidance for full-year 2019 total CF net product revenues was $3.60 billion - $3.70 billion."

16:10 EDT Vertex establishes annual Trikafta cost of $311,503 - The FDA today approved Vertex Pharmaceuticals' Trikafta, which is made up of elexacaftor, tezacaftor, ivacaftor and ivacaftor, for treatment of cystic fibrosis in patients 12 years of age and older who have at least one F508del mutation. The company has established a wholesale acquisition cost for Trikafta in the United States of $311,503 on an annual basis, or $23,896 per 28-day pack.

16:08 EDT Howard Hughes announces Transformation Plan, new executive leadership - Following a thorough review of strategic alternatives, The Howard Hughes Corporation announced that it will execute a Transformation Plan, led by new executive leadership, comprised of three pillars: (1) a $45M- $50M per annum reduction in overhead expenses, (2) the sale of approximately $2B of non-core assets, and (3) accelerated growth in the company's core MPC assets. Paul Layne, President of HHC's Central Region, has been named CEO, effective immediately. Paul Layne will replace David Weinreb on the Board of Directors. David Weinreb and Grant Herlitz will step down from the company. David O'Reilly, CFO, will have an enhanced role at the company partnering with Mr. Layne to execute on the new plan. As part of the new plan, the company will eliminate its holding-company-type organizational structure and move to a decentralized regional management model supported by a lean corporate team. HHC will consolidate its Dallas corporate headquarters with its largest regional office in The Woodlands, driving substantial cost savings and increased synergies. These changes are estimated to reduce overhead expenses by $45 - $50 million per annum, of which $40 - $45 million per annum will result from a reduction in corporate G&A, and $5 million per annum will result from a reduction in overhead costs allocated to development properties and capitalized under GAAP. One-time charges associated with relocation expenses, retention and severance payments are expected to be approximately $38 to $40 million, and will be predominantly expensed in the fourth quarter of 2019. The Company has identified approximately $2 billion of non-core assets it expects to sell over the next 12 to 18 months. The estimated $600 million of net cash proceeds from the sale, after debt repayment and transaction costs, will be used for share repurchases and development opportunities in the core MPCs. These non-core assets generated $40 million of Q2 2019 annualized NOI, and are expected to generate $66 million of stabilized NOI. For the most part, these assets are located outside of the MPCs, Ward Village and the Seaport District, and have limited competitive advantages under HHC ownership.

16:07 EDT Cadence Design CEO says industry trends driving strong design activity - "Major industry trends led by AI and data analytics are driving strong design activity, which coupled with innovation and outstanding execution by Cadence, again led to strong operating results, as Cadence delivered 9 percent year-over-year revenue growth," said Lip-Bu Tan, CEO. "Our Intelligent System Design strategy enables us to provide more capabilities and value to our customers, while also expanding our total addressable market."

16:05 EDT Embraer signs $1.4B business jet deal with Flexjet - Embraer announced a purchase agreement with Flexjet. The deal comprises a fleet of Embraer business jets, which includes the recently certified Praetor jets and the Phenom 300. The announcement was made during a press conference at the 2019 National Business Aviation Association's Business Aviation Convention and Exhibition, which is being held through October 24, in Las Vegas, Nevada. Valued at up to $1.4B, at current list prices, this deal was included in the second quarter backlog, with deliveries starting in the fourth quarter. With this purchase agreement, Flexjet becomes Embraer's Praetor Fleet Launch Customer.

16:04 EDT TD Ameritrade reports Q4 net new client assets $93B, up 7% from last year - Reports Q4 average client trades per day up 6% at 860K.

15:58 EDT Vertex announces FDA approval of Trikafta for treatment of cystic fibrosis - Vertex Pharmaceuticals announced the FDA has approved Trikafta for the treatment of cystic fibrosis, or CF, in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene, the most common CF-causing mutation. With this approval, for the first time, approximately 6,000 people with CF ages 12 years and older who have one F508del mutation and one minimal function mutation have a medicine that targets the underlying cause of their CF. Additionally, approximately 12,000 people with one or two F508del mutations who are currently eligible for one of Vertex's three other FDA-approved CF medicines are now also eligible for Trikafta. Vertex has submitted a Marketing Authorization Application to the European Medicines Agency for the elexacaftor/tezacaftor/ivacaftor combination regimen. Vertex is currently evaluating elexacaftor/tezacaftor/ivacaftor in people ages 6 through 11 with F/MF and F/F CF mutations in an ongoing Phase 3 study and is committed to evaluating elexacaftor/tezacaftor/ivacaftor in children less than6 years of age as part of planned future studies.

14:59 EDT Vertex trading halted, news pending

14:52 EDT Callaway Golf announces multi-year partnership with Stephen Curry - Stephen Curry has entered into a "unique partnership" with Callaway Golf, the golf equipment manufacturer announced. Callaway and Curry have had an "informal relationship for years centered around his passion for golf and affinity for Callaway products" and together they have committed to partnering on various initiatives Curry will undertake with a focus on expanding the game by making it more accessible to underserved and underrepresented youth, the company said. "I am beyond excited for the opportunity to work with Callaway Golf. Their ability to think outside the box on how we can collectively grow the game of golf is second to none. I can't wait to begin rolling out some of our ideas to make golf more accessible to boys and girls around the world," Curry said.

14:05 EDT Flexjet announces $1.4B jet order from Embraer - Flexjet announced that it has placed a $1.4B order with Embraer Executive Jets, a division of Embraer S.A., for the Praetor mid- and super midsized aircraft and Phenom 300 light jets. Accepting delivery of the Praetors will make for the fourth time Flexjet's management team has introduced new Embraer aircraft to the fractional market. Previous introductions were the Legacy Executive in 2003, the Phenom 300 in 2010 and the Legacy 450 in 2016. "The spirit of innovation at Embraer keeps us coming back time and again because it dovetails perfectly with our commitment to provide the youngest, most modern fleet to our Owners," said Flexjet Chief Executive Officer Michael Silvestro. "These aircraft are sure to be crowd-pleasers with their extraordinarily long range and impressive speed for aircraft of their size." In anticipation of this substantial order, Flexjet has been aggressive in recruiting pilots this year and recently met its 2019 goal of hiring 175 new pilots, the company said.

13:58 EDT Teva settles Ohio opioid cases, has framework in place to settle remaining cases - Teva Pharmaceutical Industries (TEVA) and its affiliates announced a settlement agreement with both Cuyahoga and Summit counties of Ohio. The settlement resolves the counties' claims and removes Teva from the Track 1 opioid litigation. Under the terms of the settlement, the company will provide the two counties with the critical opioid treatment medication buprenorphine naloxone, known by the brand name Suboxone, valued at $25M and distributed over three years to help in the care and treatment of people suffering from addiction and a cash payment in the amount of $20M, to be paid over three years. The company also confirms that there is an agreement in principle with a group of attorneys general from North Carolina, Pennsylvania, Tennessee and Texas, as well as certain defendants, for a global settlement framework. The framework is designed to provide a mechanism by which the company attempts to seek resolution of remaining potential and pending opioid claims by both the states and political subdivisions. Under this agreement, Teva would donate buprenorphine naloxone, in quantities of up to the amount needed to meet the majority of the currently estimated U.S. patient need over the next 10 years, with a value of approximately $23B. Buprenorphine naloxone is the primary drug used to treat opioid addiction. The Teva product donation will significantly contribute to the care and treatment of people suffering from addiction and assist impacted communities. Teva would also provide a cash payment of up to $250M over 10 years.

13:48 EDT Kingold Jewelry announces 1-for-6 reverse split of common stock - Kingold Jewelry announced the board of directors and a majority of the shareholders of Kingold approved on September 26, 2019 and October 7, 2019, respectively, a 1-for-6 reverse stock split of the company's issued and outstanding shares of common stock. As a result of the reverse stock split, there are approximately 11,018,917 shares of common stock outstanding, subject to adjustment due to the effect of rounding fractional shares into whole shares. The reverse stock split was effected solely to enable the company to expeditiously meet the NASDAQ continued listing standards relating to the minimum bid price, which the company was previously advised it was in non-compliance with, and to reduce the risk of the company being automatically delisted from the NASDAQ Capital Market due to the closing bid price of its common stock falling below $1.00 per share for 30 consecutive business days, the company stated.

13:29 EDT Vertex says Spanish government approves national reimbursement of CF combos - Vertex Pharmaceuticals announced that the Spanish Government has approved terms for the national reimbursement of ORKAMBI and SYMKEVI in combination with KALYDECO for eligible patients in Spain living with cystic fibrosis, or CF. Under the terms announced today, children ages 6 to 11 years with CF who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene can be treated with ORKAMBI. Patients ages 12 years and older who either have two copies of the F508del mutation, or one copy of the F508del mutation and a copy of one of the other 14 mutations approved within the license in which the CFTR protein shows residual activity, can be treated with SYMKEVI in combination with KALYDECO. Ludovic Fenaux, Senior Vice President, Vertex International, commented, "Today's announcement means ORKAMBI and SYMKEVI can be prescribed from the first of November 2019 for the approximately 600 eligible cystic fibrosis patients living in Spain, to treat the underlying cause of their disease. We thank the Spanish Authorities for their collaboration and commitment to working with us in an innovative way to come to a solution for patients."

12:49 EDT Facebook updates inauthentic behavior policy to counter new tactics - Facebook said in a post on its website, "While we investigate and enforce against any type of inauthentic behavior, the most appropriate way to address someone boosting the popularity of their posts in their own country may differ from the best way to counter foreign interference. That's why we're updating our inauthentic behavior policy to clarify how we act against the spectrum of deceptive practices we see on our platform...We're updating our inauthentic behavior policy to further improve our ability to counter new tactics and bad actors. Here's how we will act against a range of inauthentic activities, whether foreign or domestic, state or non-state." Reference Link

12:46 EDT Old Point Financial appoints Elizabeth Beale CFO - Elizabeth Beale has been appointed senior VP and CFO of Old Point Financial Corporation and executive VP and CFO of Old Point National Bank effective immediately. Beale has served as Old Point's interim CFO since July of this year.

12:20 EDT GlaxoSmithKline to divest rabies, tick-borne encephalitis vaccines - GlaxoSmithKline announced the divestment of travel vaccines Rabipur for the prevention of rabies, and Encepur for the prevention of tick-borne encephalitis, to Bavarian Nordic. The decision to divest these brands, acquired from Novartis in 2015 as part of the acquisition of its vaccines business, supports GSK's strategic intent to increase focus and reinvest in growth assets, innovation and a simplified supply chain in its vaccines business. GSK will receive an upfront payment of approximately EUR301M and will also receive milestone payments of EUR495M and additional proceeds from the sale of inventory over the course of the supply arrangements for a total consideration of up to EUR 955M. The value of inventory at the anticipated closing date is estimated to be EUR 159M. EUR 25M of the total consideration is conditional upon future sales performance of the two vaccines. Milestones are payable upon successful technology transfer, marketing authorization transfers and the fulfillment of GSK's supply commitments until Bavarian Nordic obtains regulatory approval to manufacture the vaccines. To ensure supply continuity both vaccines will continue to be manufactured primarily at GSK's Marburg site in Germany until full production is transferred to Bavarian Nordic. The staged technology transfer is expected to commence in Q1 2020 with completion anticipated within 5 years. No employees or manufacturing facilities are being transferred as part of this transaction. The transaction is expected to close by the end of 2019 and is conditional upon anti-trust approval as well as approval of Bavarian Nordic's rights issue by its shareholders.

12:00 EDT VelocityShares 3x Long Natural Gas ETN falls -10.8% - VelocityShares 3x Long Natural Gas ETN is down -10.8%, or -$1.56 to $12.87.

12:00 EDT Infosys falls -14.4% - Infosys is down -14.4%, or -$1.52 to $9.05.

12:00 EDT VelocityShares 3x Inv Natural Gas ETN rises 11.7% - VelocityShares 3x Inv Natural Gas ETN is up 11.7%, or $15.46 to $147.91.

11:46 EDT Hemp, Inc. highlights The Fly's interview with CEO Bruce Perlowin - Hemp, Inc. announced news coverage in a "leading digital publisher of real-time financial news," The Fly. The published article features an exclusive interview with Hemp, Inc. CEO, Bruce Perlowin, for its recent edition of "Rising High". During the conversation, Perlowin "discusses smokeable hemp; providing green solutions through a healthy, eco-friendly approach; the Company's social mission, expansion, competitive advantage, challenges and opportunities; and the critical importance of infrastructure for hemp in America," Hemp said in a statement. Reference Link

11:16 EDT Colorado ends participation in multistate lawsuit against T-Mobile/Sprint merger - Dish Network (DISH) will locate its new wireless headquarters with at least 2,000 full-time employees in Colorado and T-Mobile (TMUS) will significantly build out a statewide 5G network, particularly in rural areas, under agreements the Colorado Attorney General's office announced. The companies agree to pay up to a total of $100M if they fail to meet these commitments, the Colorado Attorney General's office said. The Attorney General's Office will end its participation in a multistate lawsuit it joined in June to halt the T-Mobile and Sprint (S) merger "because of the substantial benefits that Coloradans will gain from these commitments," the AG's office said. Reference Link

10:34 EDT DionyMed Brands receives notice of default, demand for payment - DionyMed Brands announced that GLAS USA provided the company with notice of default under the Credit Agreement and demand for immediate payment of the amount of $24,810,682.80 plus any additional interest, fees and expenses. GLAS America also concurrently provided the Company with a Notice of Intention to Enforce Security under section 244 of the Bankruptcy and Insolvency Act. GLAS America will not have the right to enforce its security over the Company and its assets until the expiry of the 10-day period after the BIA Notice was sent unless the Company consents to an earlier enforcement. The Company is reviewing and considering the Demand Notice and BIA Notice and its options. It will continue to work co-operatively with its major lender towards reaching a restructuring solution for it to continue operating as a going concern for the benefit of its stakeholders. At present, there can be no assurance as to what, if any, alternatives might be pursued by the Company and there can be no assurance that the Company will reach any solution with the Company's lender, or as to the terms of any such solution, if achieved. Holders of the Company's shares may face a loss of their investment as a result of a failure to reach a solution with the lender or as a result of a failure to reach a solution that includes holders of shares.

10:31 EDT Infosys sinks are receiving anonymous whistleblower complaints - Infosys said earlier today that is has received "anonymous whistleblower complaints alleging certain unethical practices." The company added, "These have been placed before the Audit Committee as per the Company's practice and will be dealt with in accordance with the Company's whistleblower policy." Shares of Infosys are down 13%, or $1.41, to $9.16 in early trading.

10:00 EDT Borr Drilling rises 6.9% - Borr Drilling is up 6.9%, or 44c to $6.84.

10:00 EDT VelocityShares 3x Inv Natural Gas ETN rises 13.2% - VelocityShares 3x Inv Natural Gas ETN is up 13.2%, or $17.43 to $149.88.

09:47 EDT Micro Focus falls -11.0% - Micro Focus is down -11.0%, or -$1.67 to $13.50.

09:47 EDT Infosys falls -13.9% - Infosys is down -13.9%, or -$1.47 to $9.11.

09:47 EDT Coty rises 8.7% - Coty is up 8.7%, or 88c to $11.00.

09:43 EDT Dunkin' Brands rolling out Beyond Meat breakfast sandwich nationwide - Dunkin' Brands (DNKN) announced plans to roll out its Beyond Meat (BYND) breakfast sandwich, which the company had been testing at Dunkin' Manhattan restaurants, to 9,000 U.S. restaurants starting Nov. 6. Dunkin' Brands CEO David Hoffmann said: "We are extremely proud of our partnership with Beyond Meat and thrilled to be the first U.S. quick service restaurant to offer Beyond Breakfast Sausage nationwide. Dunkin' is the brand that democratizes trends for America, and this latest addition to our menu gives consumers more choice to meet their evolving needs. The introduction of a plant-based option at our shops in Manhattan exceeded our expectations, exciting loyal fans and new customers alike. As we continue to transform our brand, we're proud to use our platform to give everyone the opportunity to enjoy the great taste and benefits of plant-based protein."

09:35 EDT Nymox says awarded patents, filings process 'steadily been moving forward' - Nymox announced that the company has received several new additional United States, European, and other jurisdictional formal patent issuances covering Fexapotide Triflutate and its use for prostate and urinary tract disorders. The effective coverage for the treatments has now been extended to 18 years into 2037 and later in the major global regions, according to the company. Nymox also reported that its efforts involved in the upcoming filings for approval for Fexapotide in the U.S. and in Europe "have steadily been moving forward." The company is currently preparing to seek similar formal clarification from the authorities on data formatting and standardization for the filings which is a necessary step and which it expects to receive in the near future. After the latter, the company expects to be able to report to shareholders with further precision about expected timelines for the two filings, Nymox said. Because the data involved in the program has extended over a very long time period, it has also generated additional requirements of data formatting updates and other specific procedures for the filings, Nymox added. Dr. Paul Averback CEO of Nymox commented, "Our team has been working diligently for many years and these intellectual property extensions are some of the fruits of our labors. For our shareholders this effectively is a major increase in the conventionally recognized timeline of proprietary rights, and thus the market exclusivity of our products and long-term valuations if approved. It is work that requires persistence, but good things normally take their time to be done properly. The best quality companies plan for and execute long-term. Nymox has strong shareholders who have provided our team with the patient support and capital needed to make these important advances."

09:27 EDT Halliburton says 'carefully' monitoring market dynamics in North America

09:24 EDT Curaleaf Holdings shareholders agree to extended lock-up - Curaleaf Holdings announced that its core shareholders representing approximately 75% of the issued and outstanding shares of the company have entered into an amended and extended lock-up agreement. Since the company's reverse takeover transaction in October 2018, all shareholders holding individually more than 1% of the issued and outstanding shares have been subject to lock-up agreements. The core shareholders have voluntarily agreed to an extended lock-up release schedule, which limits the number of shares released as of today to 15% of previously locked-up shares. Going forward, an additional 15% of the locked-up shares will unlock on the last day of each subsequent calendar quarter, with the final 10% to unlock on March 31, 2021.

09:23 EDT Halliburton sees U.S. frack equipment attrition going into 2020

09:20 EDT Halliburton sees customer activity to decline across all basins in NA in Q4 - Says the rig count and completions activity may be lower in Q4 vs. last year, cites holidays and potential weather impacts, as well as customers' free cash flow generation commitments and oversupply of gas market, as well as concerns about oil demand softness in 2020.

09:17 EDT Halliburton says U.S. E&P spending largely concentrated in 1H

09:15 EDT Halliburton says will keep reducing costs in North America operations

09:11 EDT Wintrust selects DerivativeEDGE to manage interest rate derivatives trading - Wintrust Financial Corporation has selected DerivativeEDGE, as its system of record for all interest rates derivatives trading activity. After an extensive search for the right enterprise trading technology platform, the bank partnered with Derivative Path, Inc. to enhance and streamline its commercial interest rate derivatives offering. Wintrust will leverage DerivativeEDGE to structure, execute and manage its interest rate derivatives portfolio.

09:10 EDT Assertio Therapeutics says West receives CRL from FDA on cosyntropin NDA - Assertio Therapeutics announced that its development partner West Therapeutic Development, has received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application for its injectable formulation of long-acting cosyntropin. West is seeking approval for use as a diagnostic drug in the screening of patients presumed to have adrenocortical insufficiency. The primary focus of the CRL relates to the FDA determination that certain pharmacodynamic parameters were not adequately achieved. "West and Assertio will work together to determine how best to address the CRL," said Arthur Higgins, President and CEO of Assertio. "In the meantime, we continue to focus on driving robust adjusted EBITDA performance and generating strong cash flows." Long-acting cosyntropin is an alcohol-free formulation of a synthetic analogue of ACTH, a hormone secreted from the pituitary gland that is responsible for the stimulation of the adrenal cortex. Cosyntropin is composed of the first 24 of 39 amino acids of natural ACTH and retains the full steroidogenic activity of natural ACTH.

09:08 EDT OncoSec writes letter to shareholders on $30M Grand Decade investment - OncoSec released a letter to shareholders regarding the strategic transaction with Grand Decade Developments, a direct wholly-owned subsidiary of China Grand Pharmaceutical and Healthcare and its affiliate, Sirtex Medical US. The letter states, among others: "On Thursday, October 10, 2019, we announced an important strategic transaction with China Grand Pharmaceutical and Healthcare Holdings and its U.S. affiliate, Sirtex Medical Holdings (...) upon approval of our shareholders, this transaction would bring a $30M cash infusion at a premium to our recent price per share and fund both of our ongoing Keynote clinical trials of Tavo in combination with Merck's Keytruda to completion (...) Should CGP seek to offer to acquire the outstanding shares of OncoSec within the 12 months following the closing of the transaction, the offer price for the outstanding shares of OncoSec must be the greater of $4.50 per share or 110% of the last closing stock price of the common stock on the date prior to making such an offer. This is not a right to acquire the outstanding shares of OncoSec for $4.50 or higher, but rather the ability to offer to do so. The OncoSec Board is not obligated to accept any such offer and would evaluate it based on the best interest of OncoSec shareholders at that time. In addition, following the initial transaction, CGP and Sirtex will not have a majority of the Board of Directors and would be entitled to a total of only three of nine seats on the OncoSec Board of Directors as a result of the transaction. This establishes a very favorable floor, not a ceiling, on a potential acquisition price at a significant premium from our current valuation. (...) For this transaction to be approved, an affirmative vote from a majority of OncoSec's shareholders is required. (...)"

09:07 EDT Halliburton confirms expectation for high single digit international growth - Halliburton, on its Q3 earnings conference call, confirmed its expectation of high single digit international growth for all of 2019.

09:07 EDT Seelos Therapeutics announces amendment of SLS-002 agreement - Seelos Therapeutics announced an amendment of the agreement with Vyera Pharmaceuticals for the development of SLS-002. This amendment now removes the requirement to conduct a Phase III trial and converts the one-time cash payment obligation otherwise owed to Vyera for commencement of the Phase III trial to a series a cash and stock payments over the next 9 months. Based on feedback from its Type C meeting with FDA, Seelos plans to conduct a Phase II Proof of Concept trial in Suicidality in Major Depressive Disorder.

09:05 EDT Hancock Whitney announces $185M accelerated share repurchase - Hancock Whitney Corporation announced that it has entered into an accelerated share repurchase agreement with Morgan Stanley & Co. to repurchase $185M of Hancock Whitney's common stock. Under the agreement, on October 21, 2019, Hancock Whitney will make a $185M payment to Morgan Stanley, and on the same day, will receive initial delivery of approximately 3.6M shares of its common stock. The actual number of shares to be delivered to the company in this ASR transaction will be based generally on the volume-weighted average price per share of the Hancock Whitney common stock during the term of the ASR agreement less a specified discount, subject to possible adjustments in accordance with the terms of the ASR agreement. Final settlement of the ASR agreement is scheduled to occur no later than the third quarter of 2020. The ASR will be completed under the Company's current stock buyback program, announced on September 23, 2019.

09:04 EDT Abbott: Australian Red Cross signs agreement for Alinity s System - Abbott announced the Australian Red Cross Blood Service has signed a multiple-year agreement for Abbott's most advanced blood and plasma screening technology, Alinity s System. The Australian Blood Service collects 1.5M donations each year, providing a safe blood supply to 25M Australians. The agreement also includes Abbott's total lab automation solution, as well as its informatics and professional services. The Australian Blood Service staff will use AlinIQ AMS, a product of AlinIQ Professional Services, to integrate data from multiple analyzers so staff can view it in one place, providing greater workflow efficiency and better quality control. The Alinity s system will help continuously process up to 600 tests per hour, while the lab automation solution will manage routine, manual tasks so staff can handle up to 3,600 samples per hour. The adoption of Abbott's latest technologies allows the Australian Blood Service to bring the highest levels of efficiency to their operation. By updating Abbott's previous blood and plasma screening system with Alinity s, and adding total lab automation to their facilities, the Australian Blood Service will be able to further improve workflow practices and productivity.

09:02 EDT Live Nation acquires David Grutman's Groot Hospitality - Live Nation has acquired a majority stake in David Grutman's Groot Hospitality. Groot Hospitality's portfolio includes dining, entertainment and hospitality brands and is set to expand with 11 new projects in Miami, Las Vegas, Dallas & Dubai slated to open in the next 24 months. David Grutman will remain as CEO of Groot Hospitality along with executives Chris Cuomo and Mo Garcia.

09:02 EDT Nasdaq announces retirement of vice chairman Sandy Frucher - Nasdaq announced Vice Chairman Meyer "Sandy" Frucher will conclude his 11-year tenure as Vice Chairman and assume the role of Strategic Advisor, effective January 1, 2020. Since 2008, Frucher has been responsible for global exchange relationships, as well as advising Nasdaq's senior management team on a broad range of industry and regulatory issues, in particular being a leading voice in the company's commitment to sustainability.

08:54 EDT Harvard Bioscience appoints Ken Olson as general manager, pre-clinical systems - Harvard Bioscience announced that Ken Olson has been named VP and General Manager, Pre-Clinical Systems, reporting to Chairman, President and CEO, Jim Green. Olson will lead the Pre-Clinical Systems Team, which is comprised of the Data Sciences International team focused on delivering market leading preclinical products, systems, and services to the drug discovery and development industry. Olson was formerly SVP, Global Engineering and Operations at Spacelabs Healthcare.

08:53 EDT Buckeye Partners receives all regulatory approvals for pending acquisition - Buckeye Partners announced that all regulatory approvals required to complete the acquisition of Buckeye by entities affiliated with the IFM Global Infrastructure Fund previously announced on May 10, 2019 have been received. The merger agreement relating to the proposed merger and the transactions contemplated thereby were previously approved by the affirmative vote of the holders of a majority of Buckeye's outstanding limited partner units on July 31, 2019. The completion of the proposed merger is currently expected to occur prior to market opening on Friday, November 1, 2019, subject to the provisions of the merger agreement, including the satisfaction or waiver of customary closing conditions. As previously announced, upon completion of the proposed merger, Buckeye's outstanding limited partner unitholders will receive $41.50 per unit. In accordance with the terms of the merger agreement, if the completion of the proposed merger occurs on Friday, November 1, 2019 as currently expected, Buckeye's general partner would not declare or pay a cash distribution for the quarter ended September 30, 2019.

08:52 EDT Homology Medicines presents data from investigational gene therapy programs - Homology Medicines announced the presentation of preclinical data that support its investigational gene therapy programs for the treatment of metachromatic leukodystrophy and phenylketonuria at the American Society of Human Genetics 2019 Meeting. For the first time, Homology presented preclinical data from the murine model and non-human primates that demonstrated that the HMI-202 gene therapy candidate crossed the blood-brain-barrier and the blood-nerve-barrier and increased levels of arylsulfatase a protein to therapeutic levels. In addition, preclinical data on gene therapy candidate HMI-102 showed that a single administration resulted in sustained Phe reduction and increased tyrosine and other important downstream biochemical metabolites in the PKU murine model. Highlights from the posters include: HMI-202 gene therapy in development for MLD - Single administration of HMI-202 resulted in therapeutic levels of human ARSA enzyme in the murine MLD model. HMI-202 modulated disease-relevant biomarkers through 48 weeks, including LAMP-1, myelin and lymphocyte protein transcript and sulfatides in central nervous system tissue in the murine model. Human ARSA protein levels in non-human primates confirmed crossing of the blood-brain-barrier and blood-nerve-barrier. HMI-102 investigational gene therapy for PKU - A single administration normalized blood Phe levels in the Pahenu2 murine model, which was sustained for 48 weeks, consistent with the lifespan of the model. There was a concomitant increase in downstream biochemical metabolites, including tyrosine, melanin and 5-HIAA, indicating that the metabolic pathway had been restored. Liver vector genomes were stable over time, and weight-based dosing from the murine model to the non-human primate model was confirmed. There were no adverse findings observed in a toxicology study in the murine model to the highest dose tested. This poster received a Reviewers' Choice Abstract award during the ASHG Meeting. A 5-year retrospective study of individuals with PKU treated at two specialized U.S. clinics - Phe concentrations in patients with classical PKU remained above the therapeutic threshold under current standard of care, which includes life-long dietary protein restriction. There is an unmet medical need for therapies to control blood Phe in patients with PKU.

08:47 EDT Myovant Sciences completes patient recruitment for Phase 3 SPIRIT 1 study - Myovant Sciences announced that it has completed patient recruitment for its SPIRIT 1 study, the second of two Phase 3 replicate studies evaluating relugolix combination therapy in women with endometriosis-associated pain. "The completion of recruitment for the SPIRIT program marks another important step in achieving our goal to bring a best-in-class, non-invasive treatment option to women suffering from endometriosis, that has predictable efficacy and tolerability and is potentially suitable for long-term use," said CMO Juan Camilo Arjona Ferreira. "We are extremely appreciative of the physicians and patients who participate in our clinical trials and have helped us reach this important milestone. We look forward to sharing the top-line results in the first and second quarters of 2020."

08:42 EDT Newmont Goldcorp increases ownership in Sirios to 19.9% - Management of SIRIOS RESOURCES announced the completion of a non-brokered private placement for aggregate gross proceeds of C$1,480,000 by the issuance of 7,400,000 units at CA0.20 per unit. Newmont Goldcorp has exercised its right to increase its ownership from 15.9% up to 19.9% of the share capital of Sirios on a partially diluted basis by acquiring 5,410,020 units for an amount of C$1,082,004. Each unit consists of one common share of Sirios and one-half of one share purchase warrant. Each full warrant gives the holder the right to purchase one common share at an exercise price of C$0.30 per share for eighteen months following the closing date. There will be a hold period of four months and one day on all securities issued under this placement. The TSX Venture Exchange has conditionally approved the private placement. No finder's fees were paid for the placement. Two directors of Sirios participated in the placement for a total amount of C$30,000. The proceeds of the placement will be used by Sirios for exploration fieldwork, exploration infrastructure improvements on its Cheechoo gold project as well as for general corporate and working capital purposes. Cheechoo neighbours Newmont Goldcorp's Eleonore gold mine located in Eeyou Istchee James Bay. Please refer to Sirios' website for more information on this project.

08:38 EDT Corning, Intel announce 5G in-building network collaboration - Corning Incorporated (GLW) and Intel (INTC) announced a strategic collaboration to accelerate the availability of 5G in buildings. The two companies will work together to deliver a virtual platform for Corning's 5G network solutions powered by Intel Xeon Scalable processors and Intel FlexRAN Reference Software Architecture. This co-innovation effort will create a streamlined path for mobile network operators and enterprise building owners to deploy 5G solutions that meet the performance demands of their customers and enable faster adoption of 5G applications, with the ability to scale from small to large venues and enterprises. The collaboration combines Corning's wireless connectivity portfolio and Intel's leading-edge technologies, including second-generation Intel Xeon Scalable processors, Intel FlexRAN 5G and 4G Reference Software, Intel FPGA Programmable Acceleration Card N3000, and 10/25/40Gb Intel Ethernet 700 Series Network Adapters to support 5G innovation as deployments proliferate around the world.

08:35 EDT Odonate Therapeutics completes enrollment in CONTESSA trial - Odonate Therapeutics announced the completion of enrollment in CONTESSA, a multinational, multicenter, randomized, Phase 3 study investigating tesetaxel as a potential treatment for patients with HER2 negative, hormone receptor positive metastatic breast cancer. The company expects to report top-line results from CONTESSA in Q3 of 2020.

08:33 EDT Stryker completes acquisition of Mobius Imaging, Cardan Robotics - Stryker announced it has completed the acquisition of Mobius Imaging and its sister company, GYS Tech. "Mobius Imaging and Cardan Robotics bring expertise in advanced imaging and robotics, as well as a robust product pipeline, that will provide Stryker the opportunity to increase its presence in Orthopaedics, Spine and Neurotechnology," said Spencer Stiles, Stryker's Group President, Orthopaedics and Spine. "With this acquisition, we are positioned to make healthcare better by providing more complete procedural solutions, including sales, service, and support. We remain committed to our surgeons and helping them achieve the best possible outcomes for their patients."

08:29 EDT Tetra Bio Pharma in 'active discussions' for sale, distribution of Caumz - Tetra Bio-Pharma provides an update on its initiatives to bring its Caumz inhalation drug product to the market. The previous financing has allowed Tetra to successfully lay the foundation for execution of the treatment phase of its ongoing Phase 3 clinical trial and to advance the ophthalmic program . The Serenity trial is designed to provide regulators with data from a single well-designed pivotal clinical trial for an intended use involving a serious medical condition. This data will be substantiated by Tetra's existing body of clinical and scientific data. When all diseases / indications are considered, the probability of achieving marking authorization and sales for a drug that has reached phase 3 is 58%.According to Guy Chamberland, CEO, "We have made tremendous progress and have reached the last stage of drug development. This is a major achievement for a biotechnology company." Earlier this month, the corporation announced that the US FDA granted a drug-device combination product jurisdiction for its Caumz-kit; a Caumz drug combined with the Might Medic medical device. "We are in active discussions with several North American pharmaceutical firms for the sale and distribution of Caumz across North, Central and South America. We are evaluating the best path forward for Tetra and will update shareholders once we have a definite agreement with any potential partner. We believe this is the best path forward for us, as launching a commercial product in the U.S. requires the significant financial support. Strategic partnering will be key to a successful launch of an approved Caumz-kit. Our plan is to maximize shareholder value as we move forward in developing our programs, evaluating potential partnerships, and seeking institutional support of our company," Chamberland said. As previously announced Tetra intends to submit two supplemental marketing applications in breakthrough pain and fibromyalgia. Fibromyalgia affects 4% of the entire global population. Management believes that the $2Bn estimates, which are based solely on on-label promotion of Caumz-kit within the advanced cancer pain indication are conservative. Tetra has initiated discussions with financial strategic advisors, institutional private equity partners, and increased its visibility to US pharmaceutical and biotechnology market analysts. "We have no desire to continue to initiate financing the traditional way to bring Caumz to market. For several months we have been studying various strategic investment formats and will continue to do so over the coming months as we try to find the best scenario for current share holders," Chamberland said.

08:29 EDT Smith & Nephew names former Roche Diagnostics CEO Diggelmann as CEO

08:25 EDT Avalon GloboCare enters agreement ro repurchase outstanding warrants for $1.4M - Avalon GloboCare announced plans to repurchase all of the Company's outstanding warrants, totaling approximately 1.7M warrants, for approximately $1.4M. The warrants were originally issued to third party institutional investors in connection with the registered direct offering on April 25, 2019. The transaction is expected to close on or before November 8, 2019, at which time the repurchased warrants will be retired and cancelled.

08:16 EDT Range Resources announces $100M share repurchase program - Range is announcing that its Board of Directors approved the initiation of a $100M share repurchase program, beginning in October 2019. The share repurchase program will be executed at times deemed appropriate by Range management and will be funded from asset sale proceeds, free cash flow generation, and/or other potential financial transactions as and when the repurchases occur.

08:15 EDT Taseko Mines provides update on Florence Copper project - Taseko Mines provided an operational update on its Florence Copper Project. In the last nine months, Florence personnel have commissioned the 24-hole test wellfield consisting of injection, recovery and monitoring wells, while ramping up the SX/EW Plant to design capacity. This multi-step process included the initial leaching period where hydraulic control of solutions 800-1200 feet underground, in the orebody, remained compliant with all environmental guidelines. At the same time, the process of recovering copper rich solutions from the orebody commenced, in accordance with Taseko's process design. The main recovery well is now producing copper in solution at an annualized rate of approximately 600,000 pounds per year, and the expectation is for steady improvement as the well matures. The company has engaged with the EPA and the Arizona Department of Environmental Quality to advance commercial operating permits which are expected to be granted in the summer of 2020.

08:13 EDT Omnicell announces sole source partnership with Med Center Health - Omnicell announced that Med Center Health has signed a sole source agreement to partner with Omnicell to streamline and secure its medication management process. The health system will upgrade to Omnicell XT automated dispensing cabinets to help improve security and nurse-pharmacy workflows.

08:11 EDT Opko Health, Pfizer announce Phase 3 trial of somatrogon meets primary endpoint - OPKO Health (OPK) and Pfizer Inc. (PFE) announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with growth hormone deficiency met its primary endpoint of non-inferiority to daily GENOTROPIN for injection, as measured by annual height velocity at 12 months.Top-line results from the study demonstrated that treatment with somatrogon dosed once-weekly in pre-pubertal children with GHD was non-inferior to somatropin dosed once-daily with respect to height velocity at 12 months of treatment; the least square mean was higher in the somatrogon group than in the somatropin group; the treatment difference in height velocity was 0.33 with a two-sided 95% confidence interval of the difference of. In addition, change in height standard deviation scores at six and 12 months, key secondary endpoints, were higher in the somatrogon dosed once-weekly cohort in comparison to the somatropin dosed once-daily cohort. Moreover, at six months, change in height velocity, another key secondary endpoint, was higher in the somatrogon dosed once-weekly cohort in comparison to the somatropin dosed once-daily cohort. These common measures of growth are employed in the clinical setting to measure the potential level of catch-up growth that subjects may experience relative to heights of age and gender matched peers. Somatrogon was generally well tolerated in the study and comparable to that of somatropin dosed once-daily with respect to the types, numbers and severity of the adverse events observed between the treatment arms. Immunogenicity testing and analysis of additional data are ongoing, and full results of the study will be submitted for presentation at a future scientific meeting. In 2014, Pfizer and OPKO entered into a worldwide agreement for the development and commercialization of somatrogon for the treatment of GHD. Under the agreement, OPKO is responsible for conducting the clinical program and Pfizer is responsible for registering and commercializing the product.

08:11 EDT Embraer's Phenom 300 jets serviced by Gogo Wi-Fi receives FAA approval - Embraer (ERJ) has received Supplemental Type Certification for the Gogo AVANCE L5, the inflight Wi-Fi system from Gogo (GOGO). The Phenom 300 is the first aircraft from Embraer to receive an FAA approval for an in-service fleet STC for the aftermarket. Gogo AVANCE L5 connects to Gogo's 4G network. Gogo AVANCE combines Gogo's hardware and software technology to create an aviation-grade inflight connectivity and entertainment platform.

08:08 EDT Teledyne awarded $178M operations shallow water combat submersible contract - Teledyne Technologies announced that its subsidiary, Teledyne Brown Engineering, or TBE, in Huntsville, Alabama, was awarded a sole source contract from the Naval Sea Systems Command, or NAVSEA, for the follow-on production of MK11 Shallow Water Combat Submersible, or SWCS, Systems. The contract, including all options, is valued at $178M. The SWCS System is a manned combat submersible vehicle specifically designed to insert and extract Special Operations Forces, or SOF, in high threat areas. Under the initial contract with the United States Special Operations Command, or USSOCOM, TBE successfully designed, manufactured, tested and delivered the initial Engineering Development Model, or EDM, SWCS System. Due to the success of the program's EDM Phase, USSOCOM exercised options for TBE to produce and deliver additional MK11 SWCS Production Systems. Under the new NAVSEA contract, TBE will continue production and delivery of MK11 SWCS Systems, including spare parts production and the provision of engineering and technical support services, through fiscal year 2024, if all options are exercised.

08:06 EDT Foamix announces settlement of litigation with Teva over Finacea Foam - Foamix Pharmaceuticals(FOMX) announced that, together with LEO Pharma A/S, it has entered into a settlement and license agreement with an affiliate of Teva Pharmaceuticals Industries (TEVA) to resolve pending patent litigation involving Finacea Foam. Details of the settlement agreement are confidential, and the settlement agreement is subject to the review of the Federal Trade Commission and the U.S. Department of Justice. Foamix is the owner of patents that have been licensed to LEO Pharma to market Finacea Foam, a topical prescription medicine used to treat the inflammatory papules and pustules of mild to moderate rosacea. Foamix's recently approved product AMZEEQ topical foam, 4% for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris, and its product candidates FMX103 and FCD105, are based on a different foam technology platform and different patents than those listed in the Orange Book for the foam technology used in Finacea Foam. Patent infringement litigation related to Finacea Foam continues against Taro Pharmaceuticals U.S.A., Inc. and Taro Pharmaceutical Industries, Ltd.

08:06 EDT Sophiris Bio gets positive feedback from FDA on Phase 3 prostate trial design - Sophiris Bio announced that following an End of Phase 2/ Pre-Phase 3 meeting with the United States FDA, there is agreement regarding the design of a single Phase 3 clinical trial to evaluate the potential of topsalysin as a targeted focal therapy to treat patients with intermediate risk localized prostate cancer. The Phase 3 study design agreed upon with the FDA is consistent with the design previously agreed upon with the European Medicines Agency, as reported in June of this year. The study will enroll approximately 700 patients with a confirmed diagnosis of localized intermediate risk disease, to be equally randomized to receive a single administration of either topsalysin or placebo. The primary endpoint for the study will be the proportion of patients at 12 months who have failed treatment, defined as histological progression of disease, resulting in the need for alternative therapy, as assessed by an independent central adjudication panel. In addition, the FDA has indicated that in order to receive approval, Sophiris will evaluate all patients that progress to alternative treatments for an additional 12 months, for a total of 24 months of data, post the administration of study drug.

08:05 EDT Humana and Microsoft partner for predictive healthcare solutions - Humana (HUM) and Microsoft (MSFT) announced a partnership focused on building health care solutions for Humana members. Using Microsoft's Azure cloud, Azure AI, and Microsoft 365 collaboration technologies, as well as interoperability standards, Humana will develop predictive solutions and intelligent automation to improve its members' care by providing care teams with real-time access to information through a secure and trusted cloud platform. In addition, Humana will leverage Microsoft technologies for health care-tuned natural language understanding and speech recognition to improve administrative and clinical workflows to make health care easier for members and clinician partners. As a first step in the seven-year partnership with Microsoft as Humana's preferred cloud provider, Humana will aggregate data on Microsoft Azure. Humana will also standardize productivity and collaboration tools for its 41,600 employees on Microsoft 365. Humana will leverage Microsoft Azure and Azure AI to develop on-demand and virtual medical services. The companies have committed to a multiyear R&D investment, including direct funding, dedicated R&D teams and specific co-developed projects.

08:04 EDT Coty says to use proceeds from any transaction to pay down debt

08:03 EDT NN, Inc. announces expense reduction, cash savings initiatives - NN, Inc. announced expense reduction and cash savings initiatives to help the company continue to pay down its debt and support greater growth by reinvesting in its businesses. The initiatives are expected to produce approximately $32M in annualized cash savings and include the following: streamlining facilities and reducing overall SG&A costs, which are expected to save NN approximately $10M per year when fully implemented; elimination of the quarterly dividend, which is expected to save the company approximately $12M per year; and a reduction in capital expenditures as NN returns to a more normalized level of capital spending after several years of higher investment, which is expected to generate an additional $10M of savings per year. The company expects these cost reductions to be fully realized by the second quarter of 2020. In addition to these initiatives, NN announced that it plans to refinance its existing senior credit facilities to extend the tenor of its capital structure and provide additional liquidity to allow the company to execute on these and future strategic initiatives.

08:01 EDT Bausch + Lomb launches PreserVision AREDS 2 Formula minigel eye vitamins - Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies, announced the U.S. launch of PreserVision AREDS 2 Formula minigel eye vitamins. The new minigels will replace the currently offered PreserVision AREDS 2 Formula soft gels, offering patients an easier-to-swallow option compared to the original AREDS 2 soft gels. PreserVision AREDS 2 Formula minigel eye vitamins contain the exact nutrient formula recommended by the National Eye Institute for people with moderate to advanced Age-related Macular Degeneration following the landmark AREDS2 clinical study.

07:56 EDT Edesa Biotech enrolls first patient in Phase 2b dermatitis study - Edesa Biotech announced that the first patient has been enrolled in a Phase 2b clinical trial evaluating the company's lead product candidate, EB01, as a monotherapy for patients with moderate to severe chronic allergic contact dermatitis. The U.S. Food and Drug Administration recently approved Edesa's clinical protocol and provided a "safe to proceed" letter, which formally authorized the company to begin its clinical investigation. In the first cohort, ACD patients will be treated for 28 days with EB01 cream, an investigational medicine that contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor. The adaptive-designed study will primarily evaluate the safety and efficacy of EB01 in ACD patients. Investigators will also evaluate symptom reduction, quality of life and dose-relationships among various strengths of EB01 cream as secondary and exploratory measures. Edesa plans to perform a blinded interim analysis following the completion of the first cohort to determine the total number of patients for the second part of the study.

07:46 EDT Manulife Investment Management launches new secondary investment business - Manulife Investment Management announced the launch of a new secondary investment business within its Private Markets group and has appointed Jeff Hammer and Paul Sanabria to serve as Global Co-Heads of this business. The Secondaries capability is part of Manulife's strategy to expand its comprehensive Private Markets platform, which includes Private Equity and Credit, Infrastructure, Real Estate, Timber and Agriculture.

07:39 EDT Republic Media Network, EbixCash partner for brand-integrated news studio - Republic Media Network and EbixCash announced a brand-integrated news studio - the EbixCash Studio. With this tie-up, EbixCash has partnered with the largest studio in the country with 6,000 square feet of space. As a part of this path-breaking strategy, breaking news, interviews, round-the-clock bulletins, and customized news integrations will be delivered from the EbixCash studios, which will enable the brand to penetrate over 100 million homes. EbixCash Studio will mark high visibility across all the platforms of Republic Media Network - Republic TV, Republic Bharat, Republic HD OTT, and Republic World.

07:36 EDT Plus Products appoints Ari Mackler as CSO - Plus Products announced the addition of Ari Mackler as the company's chief scientific officer. Prior to joining PLUS, Mackler was vice president of clinical development for The Wonderful Company. Mackler's position at PLUS will allow him to pursue research relationships and clinical trials with academic institutions and private partners in an effort to expand and contribute to consumer understanding of cannabis and the benefits it may provide.

07:34 EDT Dominion announces equity recapitalization of Cove Point - Dominion Energy (D) announced that it has entered into an agreement with Brookfield Super-Core Infrastructure Partners, an infrastructure fund managed by Brookfield Asset Management (BAM), in which the company will transfer a 25% non-controlling equity interest in Cove Point to Brookfield in exchange for cash consideration of just over $2B, excluding working capital. The announcement is part of Dominion Energy's previously communicated intention to establish a permanent capital structure for Cove Point. The transaction represents an implied enterprise value of $8.22B, excluding working capital, and is supportive of the company's existing operating earnings per share and earnings growth guidance. Proceeds are expected to be used for general corporate purposes including significantly reducing the annual common equity financing described at the company's investor day in March 2019. Upon transaction close, expected by the end of 2019, Dominion Energy will retain full operational control of the facility and its services, and existing customers and employees will be unaffected by this recapitalization agreement.

07:34 EDT JPMorgan announces $25M commitment to communities in India to develop skills - JPMorgan announced a $25M, five-year commitment to help low- and middle-income communities in India develop the skills needed by the country's workforce in the future. Through this commitment, and in collaboration with government and nonprofit leaders, the firm will support skills training and career education programs to equip people in India for careers in the country's high growth sectors and will be aligned to market trends in retail, healthcare and IT-enabled services. It will also support actionable research and data to inform JPMorgan's future philanthropic investments in India and share best practices on education and training programs with business, government and nonprofit leaders. As part of this commitment, JPMorgan is investing up to $10M as the first funder in a World Bank- led and managed initiative called the Skills and Training in Schools for Youth Multi Donor Trust Fund, or MDTF. The program is focused on improving the quality of skills development for young people in India and improving their transition from school to in-demand and better paying jobs. The program will support innovative models in curriculum development, appropriate training for teachers as well as career counselling for students. Pilot projects will be launched in Maharashtra and Rajasthan. JPMorgan's $25M, 5-year commitment in India is part of the firm's five-year, $350M global commitment to prepare for the future of work.

07:33 EDT Innophos Holdings agrees to be acquired by One Rock for $32 per share - Innophos Holdings announced that it has entered into a definitive agreement with an affiliate of One Rock Capital Partners, whereby One Rock will acquire all of Innophos' outstanding shares for $32.00 per share in cash in a transaction valued at approximately $932M, including the assumption of debt. The transaction has been unanimously approved by Innophos' board. The offer price represents an 18% premium to the 30-trading day volume-weighted average closing share price of Innophos' common stock ended September 9, the last trading day prior to published market speculation regarding a potential transaction involving the company. The definitive agreement includes a 30-day "go-shop" period, commencing immediately, during which Innophos, with the assistance of its legal and financial advisors, will solicit alternative acquisition proposals and potentially enter into negotiations with respect to alternative proposals. There can be no assurance that this process will result in a superior proposal or that any other transaction will be approved or completed. Innophos does not expect to disclose developments with respect to the solicitation process unless and until the board makes a determination requiring further disclosure. Under the terms of the definitive agreement, the company has suspended the payment of all dividends.

07:31 EDT Innophos Holdings agrees to be acquired by One Rock for $32 per share

07:22 EDT United Road acquires Team Drive-Away from CID Capital, terms not disclosed - United Road, in partnership with its owners, The Carlyle Group (CG) and other investors, announced the acquisition of Team Drive-Away and its affiliates Driveaway USA and Fr8 Management from CID Capital. Based in Olathe, Kansas, TDA is a national non-asset-based commercial vehicle logistics provider specializing in matching professional drivers with moves of used and new heavy-haul Class 8 trucks for sellers and buyers as well as moves to reposition and optimize fleets. TDA handles 20,000 vehicles annually via a national network of more than 500 independent contractors. Together with TDA, United Road, the largest, most diversified finished vehicle logistics provider in North America, will move over four million new, used and specialty vehicles in 2019. TDA headquarters will remain in Kansas.

07:16 EDT Henry Schein to be dismissed from Summit County opioid litigation - Henry Schein announced that the plaintiff has agreed to dismiss the Company with prejudice as a defendant in the opioid litigation involving Summit County, Ohio, presently before the U.S. District Court for the Northern District of Ohio. Henry Schein, working with Summit County, will make the donation to a Pain Management Education Foundation dedicated to making grants supporting and aggregating research around best practices for pain management, including the prescription of opioids and alternatives, and educating dentists and physicians, clinical associates, patients, and patient networks on those best practices along with the risks of opioid addiction and alternative pain management treatment options for key indications. Henry Schein will pay $250,000 of Summit County's expenses.

07:16 EDT Adtalem Global Education to sell Adtalem Educacional do Brasil to YDUQS - Adtalem Global Education announced it has signed an agreement to sell its Brazilian portfolio, Adtalem Educacional do Brasil, to YDUQS. "This transaction advances the company's strategy to become a leading workforce solutions provider, aligning Adtalem's portfolio to better address the global workforce skills gap and serve its markets in a more competitive and comprehensive way." YDUQS has agreed to acquire the business in a transaction valued at $465 million at current exchange rates. IBMEC, Damasio and Wyden will retain and continue to operate under their current brands. The agreement is subject to certain terms and conditions, including anti-trust approval from Brazil's Administrative Council of Economic Defense. The transaction is anticipated to be completed in the first half of fiscal 2021. As part of its capital allocation strategy, the company intends to use the proceeds of the sale for share repurchases and investments in organic and inorganic growth.

07:09 EDT Lithium Americas appoints Yuan Gao to board of directors - Lithium Americas announced the appointment of Dr. Yuan Gao to its Board of Directors. Gao is Vice-Chairman of the board of directors of Qinghai Taifeng Pulead Lithium-Energy Technology Co.

07:07 EDT Idera Pharmaceuticals annnounces U.S. patent for tilsotolimod - Idera Pharmaceuticals announced that the U.S. Patent and Trademark Office will issue on November 5, 2019 U.S. Patent No. 10,10,463,686 entitled "Immune Modulation With TLR9 Agonists For Cancer Treatment," which includes the Company's investigational therapy tilsotolimod. The patent includes 24 claims directed to methods of treating melanoma with intratumoral administration of tilsotolimod in combination with certain immune checkpoint inhibitor therapies including CTLA-4, PD-1 or PD-L1 proteins. The patent provides exclusivity through September 2037.

07:06 EDT Armata Pharmaceuticals announces receipt of $1.3M R&D Tax Incentive - Armata Pharmaceuticals announced that it has received a Research and Development Tax Incentive cash rebate of $1.3M from the Australian Tax Office based on Armata's R&D spending in Australia during 2018. Armata will recognize the $1.3M payment received in its financial statements for the quarter ending December 31, 2019.

07:04 EDT AstraZeneca announces FDA approval of Farxiga - AstraZeneca announced that the FDA has approved Farxiga to reduce the risk of hospitalization for heart failure, or hHF, in adults with type 2 diabetes, or T2D, and established cardiovascular disease or multiple cardiovascular, or CV, risk factors. The approval is based on results from the landmark DECLARE-TIMI 58 CV outcomes trial, or CVOT, the largest sodium-glucose cotransporter 2 inhibitor CVOT conducted to date to evaluate T2D patients with multiple CV risk factors or established CV disease. Farxiga is also under regulatory review in China with a decision anticipated in the first half of 2020.

07:03 EDT Alkermes partners with Fred Hutchinson Cancer center to evalute ALKS 4230 - Alkermes has entered into a clinical research collaboration with Fred Hutchinson Cancer Research Center for ALKS 4230, Alkermes' immuno-oncology drug candidate. ALKS 4230 is a novel, engineered fusion protein designed to selectively expand tumor-killing immune cells. The planned phase 2 multi-site trial, ION-01, is designed to estimate the response rate to ALKS 4230 in combination with the anti-PD-1 therapy Keytruda in patients with advanced or recurrent head and neck squamous cell cancer who did not achieve complete remission with an anti-PD-L antibody treatment. Secondary objectives include evaluation of the duration of response, progression-free survival, time to progression and overall survival of patients with advanced or recurrent head and neck squamous cell cancer receiving treatment with ALKS 4230 in combination with pembrolizumab. The study is expected to initiate in Q4.

07:03 EDT Teradyne to acquire AutoGuide Mobile Robots for $165M - Teradyne and AutoGuide Mobile Robots announced they have entered into a definitive agreement under which Teradyne will acquire privately held AutoGuide for $165M; $58M net of cash acquired plus $107M if certain performance targets are met extending potentially through 2022. The acquisition is expected to close in the fourth quarter of 2019, subject to customary closing conditions and regulatory approval. AutoGuide provides autonomous mobile robots for material transport of payloads up to 10,000 pounds for the manufacturing, warehouse and logistics markets. Proven at leading manufacturers and warehouse providers including Pactiv, Ford and Husqvarna, AutoGuide is expected to more than double its revenue in 2019 from approximately $4M in 2018. AutoGuide's products include the Max N10 Tugger, Pallet Stacker and SurePath fleet management software.

06:53 EDT Medtronic names Sean Salmon as EVP, Group President of Medtronic Diabetes - Medtronic announced that Sean Salmon, previously Senior Vice President and President, Coronary and Structural Heart within the Cardiac and Vascular Group of Medtronic, has been named Executive Vice President and Group President of Medtronic Diabetes, effective October 21. Salmon will serve on the company's Executive Committee and succeeds Hooman Hakami, who is leaving Medtronic. The company continues to expect the Diabetes Group to deliver low-single digit organic revenue growth in the current quarter. To ensure a seamless transition, Hakami will remain an advisor to executive leadership on an as needed basis through February 2020.

06:50 EDT Halliburton CEO says 'our organization executed effectively' in Q3 - "Our organization executed effectively in the third quarter. We managed the market dynamics and delivered our financial results as per expectations," commented Jeff Miller, Chairman, President and CEO. "Total company revenue was $5.6 billion and operating income was $536 million, representing decreases of 6% and 3%, respectively, compared to revenue and adjusted operating income in the second quarter of 2019. International revenue, which was flat sequentially, was up 10% year to date and we remain confident that we will achieve high single-digit international growth for all of 2019. International growth continues across multiple regions, benefitting both our Drilling and Evaluation and Completion and Production divisions. Our North America revenue decreased 11% sequentially driven by customer activity declines and the execution of our new playbook. I am proud of how our team performed in this challenging market. We are successfully implementing our new strategy and are focused on taking the right actions to deliver returns and cash flow for our shareholders. As the international recovery continues and the North American market matures, our strategy is allowing us to thrive in this dynamic environment, generate strong free cash flow and produce industry-leading returns," concluded Miller.

06:48 EDT Seattle Genetics says HER2CLIMB trial met primary endpoint - Seattle Genetics announced positive topline results from the HER2CLIMB trial, a randomized, double-blind, placebo-controlled, active comparator pivotal trial evaluating tucatinib. The trial compared tucatinib in combination with trastuzumab and capecitabine to trastuzumab and capecitabine alone in patients with locally advanced unresectable or metastatic HER2-positive breast cancer. Patients had previously received trastuzumab, pertuzumab and ado-trastuzumab emtansine, and 47% of the patients enrolled in the trial had brain metastases at the time of enrollment. Tucatinib is an oral, small molecule tyrosine kinase inhibitor that is highly selective for HER2. The trial met the primary endpoint of progression-free survival, showing that the addition of tucatinib was superior to trastuzumab and capecitabine alone, with a 46% reduction in the risk of disease progression or death. The trial also met the two key secondary endpoints at interim analysis. The tucatinib arm demonstrated an improvement in overall survival, with a 34% reduction in the risk of death compared to trastuzumab and capecitabine alone. For patients with brain metastases at baseline, the tucatinib arm also demonstrated superior PFS, with a 52% reduction in the risk of disease progression or death compared to those who received trastuzumab and capecitabine alone. Tucatinib in combination with trastuzumab and capecitabine was generally well tolerated with a manageable safety profile. The most frequent adverse events in the tucatinib arm included diarrhea, palmar-plantar erythrodysaesthesia syndrome, nausea, fatigue, and vomiting. Grade 3 or greater adverse events in the tucatinib arm compared to the control arm included diarrhea, increased aspartate aminotransferase, increased alanine aminotransferase, and increased bilirubin. There was no requirement for prophylactic antidiarrheals. Adverse events leading to discontinuations were infrequent in both the tucatinib arm and the control arm. Additional results are scheduled to be presented on December 11 at the 2019 San Antonio Breast Cancer Symposium.

06:06 EDT Universal Technical CEO Kimberly McWaters to retire, Jerome Grant to succeed - Universal Technical Institute announced that Kimberly McWaters has advised the board that she will retire as CEO effective October 31. The company reports that McWaters will continue to serve on the board as a non-executive director. Jerome Grant, the company's Executive Vice President and COO will become CEO and join the board on November 1. The company expects to achieve the higher end of its full year guidance for FY19, which was raised on its August earnings call.

06:03 EDT Ruhnn appoints Jacky Jinbo Wang as new CFO - Ruhnn (RUHN) has appointed Jacky Jinbo Wang as the company's new CFO, effective October 16. Most recently, Jacky Jinbo Wang served as the CAO of Red Violet (RDVT).

05:54 EDT TuanChe announces strategic partnership with Tmall Auto - TuanChe (TC) announced that it has signed a strategic partnership with Tmall Auto, the automotive arm of Alibaba Group's (BABA) Tmall. This partnership will further enable both TuanChe and Tmall Auto to collaborate and explore additional growth opportunities along China's automotive transaction value chain. "As part of the agreement, Tmall Auto will work with TuanChe to integrate its online resources, e-commerce infrastructure, and big data analysis capabilities with TuanChe's pervasive national coverage and proven track record managing offline automotive operations and sales events. Both companies also plan to jointly integrate a new data-driven, smart, online-to-offline automotive transaction service while further expanding each other's customer bases and enhancing the car-purchasing experience for consumers. In conjunction with these commitments, the Company has also become the first regional partner for Tmall Auto's Bijiabao. Bijiabao is an automotive price comparison product that offers free price quoting services to automotive shoppers online, effectively increasing the overall transparency of pricing throughout China's automotive industry."

05:28 EDT Danaher to sell certain businesses to Sartorius AG for $750M - Danaher announced that it has signed an agreement to sell its label-free biomolecular characterization, chromatography hardware and resins, and microcarriers and particle validation standards businesses to Sartorius AG for approximately $750M. The combined revenue of the businesses, which are part of Danaher's Life Sciences segment, was approximately $140M in 2018. Danaher entered into the agreement to sell these businesses as a step towards obtaining regulatory approval for its pending acquisition of the GE Biopharma business, and the closing of the Sartorius AG agreement is conditioned upon Danaher's closing its acquisition of the GE Biopharma business. Danaher's acquisition of the GE Biopharma business, the proposed regulatory remedies, the approval of Sartorius as the buyer in such remedies, and Sartorius' acquisition described above all remain subject to approvals from various regulatory authorities.

05:24 EDT Honeywell sees 7,600 new business jet deliveries over next decade - The business jet industry is expected to see strong growth in the short to medium term, supported by several new airplane models coming to the market, according to Honeywell's 28th annual Global Business Aviation Outlook. Released today, the Global Business Aviation Outlook forecasts up to 7,600 new business jet deliveries worth $248B from 2020 to 2029, down 1 to 2 percentage points from the 2018 10-year forecast. "Production ramp up on many new business jet platforms are expected to lead to a 7% increase in deliveries in 2020, following a strong projected growth in 2019 over 2018 aircraft deliveries," said Heath Patrick, president, Americas Aftermarket, Honeywell Aerospace. "We are confident that these new and innovative aircraft models will support solid growth in the short term and have a continuing impact on new business jet purchases in the midterm and long term."

04:45 EDT OpenText says not considering acquisition of Micro Focus - OpenText (OTEX) in a statement notes the recent press speculation and confirms that it is not considering a potential acquisition of Micro Focus (MFGP). Bloomberg reported on Friday afternoon that OpenText was weighing the potential deal.